Form 4: Astria Therapeutics Director Cashes Out Options Post-Merger

Astria Therapeutics director Hugh M. Cole reported the cancellation of stock options following the company's merger with BioCryst Pharmaceuticals, Inc.

Summary

• Hugh M. Cole, a director of Astria Therapeutics, Inc. (ATXS), filed a Form 4 to report changes in beneficial ownership.
• The changes are a direct result of the merger of Astria Therapeutics with Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc. ('BioCryst'), which became effective on January 23, 2026.
• At the effective time of the merger, 'In-the-Money Options' (those with an exercise price less than $13.00) became fully vested and exercisable.
• These 'In-the-Money Options' were canceled in exchange for a cash payment equal to the product of the total number of shares subject to the option and the excess of $13.00 over the option's exercise price.
• 'Out-of-the-Money Options' (those with an exercise price equal to or greater than $13.00) were canceled for no consideration.
• The filing details the cancellation of several stock options, all of which were 'In-the-Money Options' based on the $13.00 merger price.
• Specific options canceled include: 16,666 shares (exercise price $12.24), 8,333 shares (exercise price $3.00), 14,100 shares (exercise price $11.35), 14,100 shares (exercise price $9.18), and 26,550 shares (exercise price $5.79).
• The reported share numbers have been adjusted to reflect a 1-for-6 reverse stock split effected by Astria Therapeutics on August 19, 2021.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as the reporting person's in-the-money options were successfully cashed out as part of a merger, providing a realized gain. However, the cancellation of out-of-the-money options for no consideration introduces a neutral element for those specific awards.

Positives

• Hugh M. Cole received cash payments for his 'In-the-Money Options' as a result of the merger.
• The merger provided a clear liquidity event for option holders whose equity awards were in-the-money.

Negatives

• 'Out-of-the-Money Options' held by the reporting person were canceled for no consideration, meaning no value was realized from those specific awards.

Risks

• The filing itself does not detail future risks for Astria Therapeutics as it is now a wholly-owned subsidiary. For option holders, the primary risk was that their options might be out-of-the-money at the merger price, leading to no value realization.

Future Outlook

The filing does not provide forward-looking statements or guidance for Astria Therapeutics, as it now operates as a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc. The transaction reported is a final event related to the merger.

Industry Context

This filing reflects a common outcome in pharmaceutical industry mergers and acquisitions, where outstanding equity awards like stock options are addressed as part of the transaction terms. The acquisition of Astria Therapeutics by BioCryst Pharmaceuticals, Inc. indicates consolidation within the biotech sector, often driven by strategic portfolio expansion or pipeline acquisition.

Comparison to Industry Standards

• The treatment of stock options in the merger, specifically cashing out in-the-money options and canceling out-of-the-money options, is a standard practice in corporate acquisitions. For example, similar structures were seen in the acquisition of Acceleron Pharma by Merck, where equity awards were converted or cashed out based on the merger consideration.
• The 1-for-6 reverse stock split prior to the merger is also a common corporate action to adjust share price and outstanding share count, often preceding significant corporate events or to meet listing requirements.

Management Changes

Corporate Governance

Legal Proceedings

• The filing does not mention any litigation or regulatory matters.

Related Party Transactions

• The transaction is a result of a merger agreement, which is a corporate action, not a related party transaction in the typical sense of a director dealing directly with the company outside of standard compensation or corporate events.

Stakeholder Impact

• Shareholders (Astria Therapeutics): Received merger consideration as per the Agreement and Plan of Merger, leading to the company becoming a wholly-owned subsidiary of BioCryst.
• Option Holders (Astria Therapeutics): Those with 'In-the-Money Options' received cash payments, while those with 'Out-of-the-Money Options' had them canceled for no consideration.
• Hugh M. Cole (Reporting Person): Realized cash value from his in-the-money stock options.

Next Steps

• The filing reports a completed transaction related to a merger. No future actions or milestones for Astria Therapeutics are mentioned, as it is now a wholly-owned subsidiary.

Key Dates

Keywords

Astria Therapeutics, ATXS, BioCryst Pharmaceuticals, Merger, Form 4, Stock Options, Beneficial Ownership, Corporate Action, Director Transaction